AU2023220646A1 - Methods of treating prostate cancer - Google Patents

Methods of treating prostate cancer Download PDF

Info

Publication number
AU2023220646A1
AU2023220646A1 AU2023220646A AU2023220646A AU2023220646A1 AU 2023220646 A1 AU2023220646 A1 AU 2023220646A1 AU 2023220646 A AU2023220646 A AU 2023220646A AU 2023220646 A AU2023220646 A AU 2023220646A AU 2023220646 A1 AU2023220646 A1 AU 2023220646A1
Authority
AU
Australia
Prior art keywords
olaparib
subject
use according
abiraterone acetate
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023220646A
Other languages
English (en)
Inventor
Jinyu Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2023220646A1 publication Critical patent/AU2023220646A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023220646A 2022-02-15 2023-02-14 Methods of treating prostate cancer Pending AU2023220646A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268026P 2022-02-15 2022-02-15
US63/268,026 2022-02-15
PCT/EP2023/053555 WO2023156357A1 (en) 2022-02-15 2023-02-14 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
AU2023220646A1 true AU2023220646A1 (en) 2024-09-19

Family

ID=85283519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023220646A Pending AU2023220646A1 (en) 2022-02-15 2023-02-14 Methods of treating prostate cancer

Country Status (11)

Country Link
US (1) US20250134887A1 (https=)
EP (1) EP4479053A1 (https=)
JP (1) JP2025505041A (https=)
KR (1) KR20240148418A (https=)
CN (1) CN118829430A (https=)
AU (1) AU2023220646A1 (https=)
CA (1) CA3250763A1 (https=)
IL (1) IL314798A (https=)
MX (1) MX2024009923A (https=)
TW (1) TW202400267A (https=)
WO (1) WO2023156357A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer

Also Published As

Publication number Publication date
US20250134887A1 (en) 2025-05-01
EP4479053A1 (en) 2024-12-25
WO2023156357A1 (en) 2023-08-24
TW202400267A (zh) 2024-01-01
KR20240148418A (ko) 2024-10-11
CN118829430A (zh) 2024-10-22
MX2024009923A (es) 2024-08-22
JP2025505041A (ja) 2025-02-19
IL314798A (en) 2024-10-01
CA3250763A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
Patnaik et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
EP3609497B1 (en) Niraparib, abiraterone acetate and prednisone for treating prostate cancer
US20250235451A1 (en) Methods of Delaying Pain Progression And Treating Prostate Cancer
EP4618990A1 (en) Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)
US20250134887A1 (en) Methods of treating prostate cancer
WO2023175477A1 (en) Treatment of breast cancer with amcenestrant
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан
HK40064914A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2022192796A1 (en) Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration
HK40092155A (en) Combination therapy for prostate cancer
HK40010824A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1209627B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan